



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy Phone 503-947-5220 | Fax 503-947-1119

Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, October 2nd, 2025

1:05 PM - 4:45 PM

Via Zoom webinar

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Stacy Ramirez, PharmD; Samara Stevens, ND; Bridget Bradley, PharmD; Douglas Carr, MD; Pat DeMartino, MD; Russ Huffman, PMHNP; Tim Langford, PharmD; Cat Livingston, MD; Eriko Onishi, MD; Eddie Saito, PharmD; Jeanne Savage, MD;

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Dan Hartung, PharmD; Megan Herink, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Trevor Douglass, DC; Lan Starkweather, PharmD; Brandon Wells; Kyle Hamilton; Michael Yu, DC; Rose Hong, PharmD Candidate

Audience: Jessica Jay*, Vertex; Carla McSpadden*, Galaderma; Kathryn Disney*, Amgen; Valerie Ng*, LEO Pharma; Adam Furman*, Sanofi; Rochelle Yang, Teva; Shannon DiBartolo*, Amgen; Rick Melby*, UCB; Erin Nowak*, Abbvie; Gary Parenteau*, Dexcom; Jenna Doerr, Artia Solutions; Connie Brooks, Galaderma; Michael Foster, Ultragenyx; Shawn Akey; Dale Fisher; Cari Hall, Merck; Lee Stout, Chiesi; Bill McDougall, Biogen; Brent Fushimi; Lewis Backus, OHA; Shauna Wick; Melissa Snider, Gilead; Gloria Zepeda, AllCare; Divine Marcelo, Amgen; Aaron Feyos, BMS; Lisa Pulver; Jennifer Lankford, Lily; Reya Nematian; Shannon Sturtevant; Lynda Finch, Biogen; Chris Ferrin, IHN; Rosalie Elliott, Umpqua Health; Oyinda; Ann Nelson; Kim-Giau Tran, Trillium; Christine Dube; Brett Freund; Matt Prokop; Courtney Cooper, OHSU; Mark Kantor, AllCare Health; Jen Tamburo; Herbeert Starr; Amy Hale, J&J; Aliethia McLeod, Trillium; Drew Larson, OHSU; Jill Carroll, BMS;

(*) Provided verbal testimony

I. CALL TO ORDER

- A. Roll Call & Introductions
 - Meeting called to order at approx. 1:05 p.m., introductions by Committee and staff
 - B. Conflict of Interest Declaration – no new conflicts of interest were declared
 - C. Approval of Agenda and August Minutes presented by Roger Citron, RPh
- ACTION: Motion to approve, 2nd, all in favor**



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy Phone 503-947-5220 | Fax 503-947-1119

D. Department Update provided by Andrew Gibler, PharmD

II. CONSENT AGENDA TOPICS

A. P&T Annual Report

B. CMS Annual Report

C. Iron Replacement, Oral Literature Scan

Recommendations:

- No changes to the PDL are recommended based on review of the evidence
- Maintain ferric maltol as nonpreferred on the PDL
- Evaluate costs in executive session

D. Multiple Sclerosis Literature Scan

Recommendations:

- Maintain Ocrevus Zunovo™, and Tyruko® (natalizumab biosimilar) as non-preferred and add to the **Multiple Sclerosis, Injectable Drugs** PA criteria
- No other changes to the PDL are recommended based on review of the evidence
- Based upon FDA safety alerts, revise the **Multiple Sclerosis, Oral Drugs** PA criteria to include a skin exam prior to initiation of S1P receptor modulators
- Evaluate costs in executive session

E. Oncology Prior Authorization (PA) Updates

Recommendation:

- Add: Modeyso™ (dordaviprone) and Hernexeos® (zongertinib) to Table 1 in the **Oncology Agents** PA criteria

ACTION: Motion to approve, 2nd, all in favor

III. NEW BUSINESS

A. Oral Cystic Fibrosis Modulators Class Update: Megan Herink, PharmD

Recommendations:

- Maintain Alyftrek as non-preferred on the PDL
- Add to the **Cystic Fibrosis Modulators, Oral** PA criteria and update with new indications and dosing and to address appropriate step-therapy based on current guidelines
- Evaluate comparative costs in executive session

Public Comment: Jessica Jay, Vertex

ACTION: Motion to approve, 2nd, all in favor

B. Targeted Immune Modulators (TIMs) for Asthma and Atopic Dermatitis (AD) Class Update and New Drug Evaluations: Deanna Moretz, PharmD and Dan Hartung, PharmD

Recommendations:

- Update the **Targeted Immune Modulators for Severe Asthma and Atopic Dermatitis** PA criteria to:
 - Include Ebglyss, Nemluvio, and expanded indications for dupilumab and mepolizumab



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy Phone 503-947-5220 | Fax 503-947-1119

- Define coverage of Chronic spontaneous urticaria (CSU) under EPSDT
- Remove requirement for co-prescribed EpiPen for all TIMs except omalizumab
- Remove required trial of an oral immunosuppressant before initiating dupilumab for management of AD in adolescent and pediatric patients
- Maintain nemolizumab and lebrikizumab as non-preferred on the PDL
- Evaluate comparative costs in executive session

Public Comment: Carla McSpadden, Galderma; Kathryn Disney, Amgen; Valerie Ng, LEO Pharma; Adam Furman, Sanofi

ACTION: Motion to approve, 2nd, all in favor

C. Targeted Immune Modulators Class Update: Deanna Moretz, PharmD

Recommendations:

- Modify **Targeted Immune Modulators for Autoimmune Conditions** PA criteria as proposed to include expanded indications for recent FDA approvals and reflect recent recommendations from published guidelines
- Consider whether another higher efficacy treatment for UC should be preferred along with adalimumab based upon American Gastroenterological Association 2024 guidance
- Evaluate comparative costs in executive session

Public Comment: Rochelle Yang, Teva; Shannon DiBartolo, Amgen; Rick Melby, UCB; Erin Nowak, Abbvie

ACTION: Motion to approve, 2nd, all in favor

D. Non-drug Item Evaluation of Omnipod® (tubeless insulin pump): Kathy Sentena, PharmD

Recommendations:

- Designate the OP5 as non-preferred and implement proposed **Omnipod Insulin Pump** PA criteria

ACTION: Modify renewal criteria to assess compliance instead of A1C goals; and remove quantity limit for PODs

Motion to approve, 2nd, all in favor

E. Non-drug Item Evaluation of Continuous Glucose Monitoring Devices: Sara Fletcher, PharmD

Recommendations:

- Update the **Continuous Glucose Monitoring (CGM)** PA criteria as proposed
- No changes to the PDL are recommended based on review of the evidence
- Evaluate comparative costs in executive session

Public Comment: Gary Parenteau, Dexcom

ACTION: Motion to approve, 2nd, all in favor

F. Sleep-wake Medications for Hypersomnia and Shift Work Disorder Class Update: Dave Engen, PharmD

Recommendations:

- Add all sodium oxybate formulations to the **Sleep-Wake Medication** PDL class
- Update **Sleep-Wake Medications** PA criteria as proposed and apply criteria to all sodium oxybate formulations
- Evaluate comparative costs in executive session



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy Phone 503-947-5220 | Fax 503-947-1119

ACTION: Motion to approve, 2nd, all in favor

**G. Antifungals Class Update
Topic Deferred**

IV. EXECUTIVE SESSION

Members Present: Stacy Ramirez, PharmD; Samara Stevens, ND; Douglas Carr, MD; Pat DeMartino, MD; Russ Huffman, PMHNP; Tim Langford, PharmD; Cat Livingston, MD; Eriko Onishi, MD; Eddie Saito, PharmD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Brandon Wells

V. RECONVENE for PUBLIC RECOMMENDATIONS

A. Oral Iron Replacement

Recommendation: Make all single ingredient iron products costing less than \$0.25 preferred. This includes formulations of:

- ferrous gluconate tablets
- iron polysaccharide complex capsules, liquid, chewable tablets, and tablets
- ferrous fumarate tablets and chew tablets
- ferrous sulfate ER tablet, solution, drops, elixir

ACTION: Motion to approve, 2nd, all in favor

B. Multiple Sclerosis

Recommendations: Make no changes to the PDL

ACTION: Motion to approve, 2nd, all in favor

C. Oral Cystic Fibrosis Modulators

Recommendations: Make no changes to the PDL

ACTION: Motion to approve, 2nd, all in favor

D. Targeted Immune Modulators for Asthma and Atopic Dermatitis

Recommendations: Make no changes to the PDL

ACTION: Motion to approve, 2nd, all in favor

E. Targeted Immune Modulators

Recommendation: Make generic infliximab preferred (Tier 1), make one ustekinumab biosimilar (Pyzchiva[®], vial and syringe) preferred, Tier 2, and make guselkumab (Tremfya[®]) preferred, Tier 2.

ACTION: Motion to approve, 2nd, all in favor



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy Phone 503-947-5220 | Fax 503-947-1119

F. Continuous Glucose Monitors

Recommendations: Make Freestyle Libre and Dexcom preferred; make all other products non-preferred

ACTION: Motion to approve, 2nd, all in favor

G. Sleep-wake Medications

Recommendations: Make no changes to the PDL

ACTION: Motion to approve, 2nd, all in favor

VI. ADJOURN – Meeting concluded at approximately 4:20 p.m.